Suppr超能文献

透析液癌抗原125浓度作为慢性腹膜透析患者腹膜状态的标志物

Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.

作者信息

Krediet R T

机构信息

Department of Medicine, Academic Medical Center, University of Amsterdam, The Netherlands.

出版信息

Perit Dial Int. 2001 Nov-Dec;21(6):560-7.

Abstract

OBJECTIVE

This study reviews publications on the history of cancer antigen 125 (CA125), the background of its use as a marker of mesothelial cell mass, determination in peritoneal effluent, and its practical use in both the follow-up of peritoneal dialysis (PD) patients and as a marker of in vivo biocompatibility of dialysis solutions.

DESIGN

Review article.

RESULTS

CA125 is a high molecular weight glycoprotein. Previous studies in ascites suggested its release by mesothelial cells. In vitro studies with cultured mesothelial cells showed constitutive production, the majority of which was dependent on mesothelial cell mass. Serum CA125 is normal in PD patients, but its concentration in peritoneal dialysate suggests local release, probably from mesothelial cells. Effluent CA125 can be considered a marker of mesothelial cell mass in stable PD patients, but large amounts are found during peritonitis, due probably to necrosis of mesothelial cells. The majority of studies found no relationship between dialysate CA125 and peritoneal transport parameters. Some cross-sectional studies reported a relationship with duration of PD, but others were unable to confirm this, due probably to the large interindividual variability. Longitudinal follow-up has shown a decrease in dialysate CA125, indicating loss of mesothelial cell mass. Application of theoretically more-biocompatible PD solutions causes an increase in dialysate CA125.

CONCLUSIONS

Dialysate CA125 is a mesothelial cell mass marker. The concentration of CA125 should be determined after a standardized dwell. A single low value is not informative. A decrease with time on PD suggests loss of mesothelial cell mass. Dialysate CA125 is a marker of in vivo biocompatibility of (new) dialysis solutions. More research is necessary on the best methodology for measuring low concentrations and establishing normal values and a significant change.

摘要

目的

本研究回顾了关于癌抗原125(CA125)的历史、其作为间皮细胞量标志物的应用背景、在腹腔积液中的测定以及在腹膜透析(PD)患者随访和作为透析液体内生物相容性标志物方面的实际应用的相关文献。

设计

综述文章。

结果

CA125是一种高分子量糖蛋白。既往腹水研究提示其由间皮细胞释放。对培养的间皮细胞进行的体外研究显示其组成性产生,其中大部分依赖于间皮细胞量。PD患者血清CA125正常,但其在腹膜透析液中的浓度提示局部释放,可能来自间皮细胞。在稳定的PD患者中,腹透液CA125可被视为间皮细胞量的标志物,但在腹膜炎期间会发现大量CA125,这可能是由于间皮细胞坏死所致。大多数研究发现透析液CA125与腹膜转运参数之间无关联。一些横断面研究报告其与PD持续时间有关,但其他研究无法证实这一点,可能是由于个体间差异较大。纵向随访显示透析液CA125降低,表明间皮细胞量减少。应用理论上生物相容性更好的PD溶液会导致透析液CA125升高。

结论

透析液CA125是间皮细胞量的标志物。应在标准化留腹后测定CA125浓度。单次低值无意义。随着PD时间延长而降低提示间皮细胞量减少。透析液CA125是(新型)透析液体内生物相容性的标志物。对于测量低浓度、建立正常值以及确定显著变化的最佳方法,还需要进行更多研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验